Fresh analysis indicates that individuals who come off new slimming jabs like semaglutide or tirzepatide can put back on reduced body mass far faster than those who stop traditional diet and exercise programs.
Published data in a major health publication shows that while obese individuals often shed a large proportion of their total mass while using the jabs, the weight is regained at an estimated rate of 0.8 kg per month once they quit.
"Individuals buying these treatments need to be cognizant of the potential of fast weight regain when the therapy is stopped," warns lead investigator Dr. Susan Jebb.
That rate of regain means a return to pre-treatment mass in about 18 months.
Weighing Treatments
The analysis, which examined dozens of studies involving thousands of patients, contrasted the results of GLP-1 agonists with other pills.
Scientists emphasize that individuals who shed pounds through dieting usually have a slower creep back—perhaps 100 grams monthly—once they finish.
The Reason for the Rapid Rebound
Nutrition scientists believe the way of the injections is key to understanding the accelerated regain.
GLP-1 drugs copy a body's own chemical called GLP-1, which controls feelings of fullness.
"Artificially providing the hormone concentrations several times higher than the body's typical production may cause the system to produce less of its own natural GLP-1, and could diminish responsiveness to its actions," said Dr. Adam Collins, a nutrition researcher.
"Withdrawal of this hormone supplement means hunger is unsuppressed, making excessive eating much more probable."
A Chronic Issue?
Medical guidelines suggest the jabs for people with weight-linked health risks, accompanied by prescribed lifestyle changes.
Many experts say that, due to the significant potential of relapse, the therapy might need to be long-term.
This perspective is reinforced by pharmaceutical companies, who state that the results "underscore the persistent character of excess weight," similar to managing conditions like diabetes.
User Testimonies
Individuals who have stopped the jabs explain a sudden resurgence of appetite.
"It felt as if a trigger activating and I was suddenly ravenous," recalled an individual.
The struggle is compounded if patients have not established sustainable dietary or behavioural changes during treatment.
Significant Interest
Figures indicate that millions of people in the UK have used weight-loss jabs in the past year, with interest continuing to grow.
- Adoption is more common among females compared to men.
- The middle-aged age group shows the highest usage rates.
- Many obtain the drugs through private prescriptions rather than public health services.
Ultimately, researchers caution that while GLP-1 drugs are powerful agents for weight loss, they are not a permanent solution and maintained weight loss hinges on combined lifestyle changes.
